Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

First International Summit on Interventional Pharmacoeconomics

Allen S. Lichter, MD, of the Value in Cancer Care Consortium, interviews Clifford A. Hudis, MD, Chief Executive Officer of ASCO, on the question of whether cancer drug prices in the United States are the problem, or just the symptom, of a larger systemic issue.

Welcome and Introduction to Vi3C

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Clifford A. Hudis, MD, and Allen S. Lichter, MD, on Oncology Drug Pricing in the United States: What You Need to Know

Related Videos

Welcome and Introduction to Vi3C

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia

Predicting Future Breast Cancer Outcomes Efficacy of a Polygenic Risk Score

Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC

Use of Obecabtagene Autoleucel CAR T-Cell Therapy for B-Cell Acute Lymphocytic Leukemia

Contemporary Management of Chronic Myeloid Leukemia, According to Hagop M. Kantarjian, MD, FASCO